FY24 rare cancer research program
Ended Awarded Last action
- Contract number
- HT942524F0215
- Awardee
-
Leidos, Inc. UEI QLNMVC12KWY3 Part of Leidos Holdings, Inc.
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $306,129
Award facts
- Opportunity
-
- Meeting, Programmatic, and Administrative Support Services Pre-Solicitation · W81XWH22R0025 · Posted Aug 16, 2021
- Contract value 79% obligated
- $389,605.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Reston, VA 20190, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$43,069 | |
| Funding Only Action | -$40,408 | |
| Original award | $389,606 |
About this award
The Defense Health Agency awarded a delivery order valued at $389,605.56 to Leidos, Inc. under the FY24 Rare Cancer Research Program on June 24, 2024. This cost-plus-fixed-fee contract is scheduled for completion by June 23, 2025, and will be performed in Herndon, Virginia. The award represents task order activity under Leidos' existing relationship with the Defense Health Agency and supports the department's medical research initiatives focused on rare cancer investigation and treatment advancement.
No small business set-aside designation was applied to this delivery order, reflecting Leidos' competitive standing as a large, established government contractor. Leidos, Inc., operating through its Leidos Services Operating Segment (doing business as SAIC), brings extensive experience in medical research program support across multiple disease areas and conditions. The parent company, Leidos Holdings, Inc., maintains a broad portfolio of Defense Health Agency contracts supporting research in cancer, infectious diseases, and rare disease investigations, positioning the prime contractor to effectively execute this rare cancer research initiative within the established performance timeline.
Quick answers
Who was awarded contract HT942524F0215?
HT942524F0215 was awarded to Leidos, Inc. by Defense Health Agency (Department of Defense) on June 24, 2024.
How much is contract HT942524F0215 worth?
The government has obligated $306,129 on HT942524F0215. Its current value, with exercised options, is $389,606.
Is contract HT942524F0215 an order under another contract?
Yes. HT942524F0215 is a delivery order under HT942523D0002, an indefinite delivery contract.
Was contract HT942524F0215 competed?
The extent of competition for HT942524F0215 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award